[Skip to Content]

Claim CME

Hematology

Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma

Educational Objective
To identify the key insights or developments described in this article

1 Credit CME

JAMA Network Open

Published Online: November 23, 2021

Research Letter

Article Information and Disclosures

Lindsey Wang^1,2;

Nathan A. Berger, MD^2,3;

Rong Xu, PhD^1,3

Author Affiliations

¹Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, Ohio
²Center for Science, Health, and Society, School of Medicine, Case Western Reserve University, Cleveland, Ohio
³Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio

Read article on JAMA Network

Read Article Claim CME

Data from early in the COVID-19 pandemic when vaccines were not available showed that patients with multiple myeloma (MM) were at increased risk for COVID-19 infection and severe outcomes.¹^,2 Recent studies showed a low rate of seroconversion after messenger RNA (mRNA) anti-SARS-CoV-2 vaccination in patients with MM and other hematological malignant neoplasms.³^,4 However, the risk and outcomes of SARS-CoV-2 breakthrough infection in vaccinated patients with MM remains unknown.

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Accepted for Publication: October 11, 2021.

Published: November 23, 2021. doi:10.1001/jamanetworkopen.2021.37575

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Wang L et al. JAMA Network Open.

Corresponding Authors: Nathan A. Berger, MD, Center for Science, Health, and Society, 2103 Cornell Rd, Cleveland, OH 44106 (nab@case.edu); Rong Xu, PhD, Center for Artificial Intelligence in Drug Discovery, 2103 Cornell Rd, Cleveland, OH 44106 (rxx@case.edu).

Author Contributions: Dr Xu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Wang, Xu.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Wang, Xu.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Wang.

Obtained funding: Berger, Xu.

Administrative, technical, or material support: Xu.

Supervision: Berger, Xu.

Conflict of Interest Disclosures: Dr Berger reported grants from the National Institutes of Health (NIH) during the conduct of the study. No other disclosures were reported.

Funding/Support: We acknowledge support from NIH National Cancer Institute R25CA221718, American Cancer Society Research Scholar Grant RSG-16-049-01 – MPC, NIH National Institute of Aging R01 AG057557, R01 AG061388, R56 AG062272, National Institute on Alcohol Abuse and Alcoholism (grant No. R01AA029831), The Clinical and Translational Science Collaborative (CTSC) of Cleveland 1UL1TR002548-01, Case Comprehensive Cancer Center P30 CA043703, Case Comprehensive Cancer Center Cancer Health Disparities SPORE Planning Grant P20 CA2332216.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We would like to thank David C Kaelber, MD, PhD, MPH, from The MetroHealth System and Case Western Reserve University for facilitating our access to TriNetX.

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.